Could a drug for acromegaly protect kidneys in polycystic disease?
NCT ID NCT02127437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested whether lanreotide, a drug that blocks certain growth hormones, can slow the loss of kidney function in people with autosomal dominant polycystic kidney disease (ADPKD). The study included 159 adults with moderate kidney decline. Participants received either lanreotide injections or a placebo every 4 weeks for 3 years. The main goal was to see if lanreotide could reduce the rate of kidney function decline by at least 30%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lanreotide
What this could lead to
If successful, lanreotide could offer a new treatment to slow kidney function loss in people with ADPKD, potentially delaying the need for dialysis or transplant.
What could go wrong
This is a completed Phase 3 trial, but results are not yet widely confirmed. Lanreotide may not slow kidney decline enough to be clinically meaningful, and side effects like gallstones or injection-site reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Necker hospital
Paris, 75015, France